CytoJounal quiz case: Fine-needle aspiration of peripancreatic mass clinically mimicking a lymphoma.

A 74-year-old male is found to have hypermetabolic upper abdominal lymphadenopathy clinically suspicious for lymphoma. After obtaining the consent, fine-needle aspiration (FNA) of the mass is performed, and ThinPrep slide and a cell block are prepared for evaluation. ThinPrep shows atypical cells with abundant pale cytoplasm, stippled chromatin, and mild anisonucleosis. The cell block shows clusters of cells with pale cytoplasm and somewhat granulomatous appearance [Figure 1]. An exhaustive immunohistochemical panel shows cells negative for AE1/3, TTF1, Hep Par, CD21, Cd1a, DOG1, inhibin, S100, and calretinin. The cells are positive for synaptophysin (image included) and chromogranin [Figure 2]. Rare cells are positive for SOX10.

Figure 1

(a) ThinPrep (×400) shows cells with abundant cytoplasm and stippled chromatin. (b) ThinPrep (×400) – the cells exhibit mild anisonucleosis

Figure 2

(a) Cell block reveals cluster of cells with pale cytoplasm and granuloma-like formation. (b) Immunohistochemistry for synaptophysin

QUESTION

What is your interpretation?

Metastatic neuroendocrine carcinoma

Solid pseudopapillary carcinoma

Adrenal cortical carcinoma

Paraganglioma

Melanoma.

ANSWER AND FOLLOW-UP OF THE CASE

Based on the cytologic features, immunohistochemistry results, and location, the correct interpretation is C. paraganglioma.

The differential diagnosis based on the careful morphologic examination and location of the tumor includes hepatocellular carcinoma, pancreatic neuroendocrine tumor, adrenocortical carcinoma, melanoma, epithelioid gastrointestinal tumor, histiocytic lesions, and paraganglioma.

Paraganglioma is a rare tumor arising from the chromaffin cells in extra-adrenal sites. They can arise in all age groups with a peak incidence in the 4th and 5th decades. Cytologic diagnosis of extra-adrenal paraganglioma presenting as a peripancreatic mass is challenging with a high error rate due to its rarity.[1] Diagnosis on cytologic (FNA specimens) is usually challenging. To render the correct diagnosis, the pathologist should keep in mind the anatomic location and cytologic features reminiscent of an endocrine neoplasm. If the possibility of paraganglioma arises during on-site evaluation, it is necessary to collect cell block material and perform the immunostains to establish the diagnosis.[2] The diagnosis can be correctly established when the lesion is morphologically suspected on smears/Thinprep and cell block material. The tumor is positive for neuroendocrine markers, and usually, S100 protein is immunoreactive in sustentacular cells. However, in this case, S100 is noncontributory, but SOX10 is positive in rare sustentacular cells. In addition, succinate dehydrogenase (SDH) beta subunit is retained by immunohistochemistry in our case.

ADDITIONAL QUIZ QUESTIONS

Q2. How would you classify tumor of adrenal medulla arising from the chromaffin cells and how often are they malignant?

Paraganglioma: 30% are malignant

Pheochromocytoma: 90% are malignant

Pheochromocytoma: 10% are malignant

Cortical adrenal tumor: 40% are malignant.

Q3. In addition to immunohistochemical findings for diagnostic purposes, what other immunohistochemistry stain is recommended if available?

Catecholamine

Cytokeratin

Melan A

SDH beta subunit.

Q4. Paraganglioma syndrome is associated with following syndromes:

von Hippel–Lindau (VHL)

Carney triad

Alport syndrome

Pheochromocytoma/paraganglioma syndrome

A, B, D

All of the above.

ANSWERS AND BRIEF REVIEW OF THE TOPIC

Q2: C Q3: D Q4: E

Neoplasms arising from the chromaffin cells in the adrenal medulla are classified as pheochromocytoma. Both paraganglioma and pheochromocytoma can produce and secrete catecholamines, thus presenting with hypertension.[3] About 90% of pheochromocytoma are benign and about 10% are bilateral. In typical paraganglioma/pheochromocytoma presentations (with hypertension), the first line of diagnosis is computed tomography (CT) scan. Functional imaging with 123I-MIBG or 18F-fludeoxyglucose positron emission tomography/CT is also acceptable if no lesion can be identified by morphological cross-sectional imaging or if metastatic disease is suspected.

Octreoscan is excellent in the investigation of paraganglioma and neuroendocrine tumors in general.[4]

In benign lesions, surgery is the first line of treatment.

Paragangliomas can be sporadic or familial and associated with various syndromes such as VHL disease, Carney triad, neurofibromatosis type 1, MEN 2A and 2B, and hereditary pheochromocytoma/paraganglioma syndrome associated with SDH gene mutations. Familial forms of pheochromocytoma/paraganglioma syndrome can be frequently clinically recognized by the younger age of onset (<45), multiple and multifocal tumors, recurrent tumors, and family history of such tumors.

It is currently thought, according to some studies, that 65%–80% of all pheochromocytomas/paragangliomas are associated with somatic or germline mutations and some can further be associated with one of the above syndromes.[5] The American Society of Clinical Oncology recommends offering genetic screening for all patients with a risk of at least 10% of carrying a genetic mutation, especially when the results aid in diagnosis or influence the management of the patient or family members at hereditary risk of cancer.[6] Some authors suggest that genetic screening should be performed in all patients with a paraganglioma.[5]

Pheochromocytoma/paraganglioma syndrome is associated with a mutation in one SDH subunit that plays a critical role in mitochondria.

Immunohistochemistry for SDHB has been shown to be an excellent screening tool for a mutation in SDH genes. Immunohistochemistry for SDHB is lost whenever there is a complete inactivation of SDHA, SDHB, SDHC, SDHD, or SDHAF2. As a result, loss of tumoral immunohistochemical staining for SDHB occurs when there is germline mutation of SDHA, SDHB, SDHC, or SDHD accompanied by inactivation of the normal allele. This makes loss of staining for SDHB a sensitive marker, suggestive of germline pathogenic variants of any of the SDH subunits.[78] Germline pathogenic variants in SDHA show loss of staining for SDHA, in addition to loss of staining for SDHB.[9] In conclusion, negative/loss of staining for SDHB is an absolute indication for genetic testing and also indicates high risk of malignant behavior.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

COMPETING INTERESTS STATEMENT BY ALL AUTHORS

The authors declare that they have no competing interests.

AUTHORSHIP STATEMENT BY ALL AUTHORS

Adela Cimic MD-primary author, data collection and drafting of the manuscript. Natasha Rekhtman, MD, senior author, data review and review of the manuscript.

ETHICS STATEMENT BY ALL AUTHORS

This study was conducted with approval from the Institutional Review Board (or its equivalent) of all the institutions associated with this study as applicable. Authors take responsibility to maintain relevant documentation in this respect.

LIST OF ABBREVIATIONS (In alphabetic order)

CT - Computed tomography,

FNA - Fine needle aspiration,

SDH - Succinate dehydrogenase,

VHL - Von Hippel-Lindau.

EDITORIAL/PEER-REVIEW STATEMENT

To ensure the integrity and highest quality of CytoJournal publications, the review process of this manuscript was conducted under a double-blind model (the authors are blinded for reviewers and vice versa) through automatic online system.